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Abstract
Background: Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia and represents a
major burden to the livestock industry. Virulence can largely be attributed to the secretion of a series of haemolytic
toxins, which are highly immunogenic. A. pleuropneumoniae also encodes a cytoplasmic N-glycosylation system,
which involves the modification of high molecular weight adhesins with glucose residues. Central to this process is
the soluble N-glycosyl transferase, ngt, which is encoded in an operon with a subsequent glycosyl transferase, agt.
Plasmid-borne recombinant expression of these genes in E. coli results in the production of a glucose polymer on
peptides containing the appropriate acceptor sequon, NX(S/T). However to date, there is little evidence to suggest
that such a glucose polymer is formed on its target peptides in A. pleuropneumoniae. Both the toxins and glycosylation
system represent potential targets for the basis of a vaccine against A. pleuropneumoniae infection.
Results: In this study, we developed cytoplasmic glycoengineering to construct glycoconjugate vaccine candidates
composed of soluble toxin fragments modified by glucose. We transferred ngt and agt to the chromosome of
Escherichia coli in order to generate a native-like operon for glycoengineering. A single chromosomal copy of ngt and
agt resulted in the glucosylation of toxin fragments by a short glycan, rather than a polymer.
Conclusions: A vaccine candidate that combines toxin fragment with a conserved glycan offers a novel approach to
generating epitopes important for both colonisation and disease progression.
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Background
Actinobacillus pleuropneumoniae is the causative agent
of porcine pleuropneumonia, which represents a signifi-
cant burden to the pig industry worldwide. A. pleuro-
pneumonia infections are highly contagious, often fatal
and are characterised by necrotic and haemorrhagic lung
legions. Sixteen serotypes have been implicated in causing
disease, classified based on their capsular polysaccharide
composition [1–3]. A. pleuropneumoniae virulence is
largely attributed to the secretion of proteins ApxI, ApxII,
ApxIII and ApxIV, which are members of the RTX family
of pore-forming toxins [4]. Each serotype encodes and se-
cretes each toxin in various combinations. While all sero-
types are capable of causing disease, those that express
ApxI and ApxII (1, 5, 9, 11, and) display greater virulence
[4, 5]. No serotype identified to date encodes all 4 toxins.
Apx toxins are highly immunogenic and animals in-
fected with A. pleuropneumoniae induce a strong pro-
duction of reactive antibodies [6]. Consequently, the
toxins represent the best candidates for effective vac-
cines against infection. The importance of Apx toxins as
vaccine candidates has been demonstrated in a number
of studies [7–12]. Currently, licensed vaccines are a mix-
ture of these toxins (inactivated), combined with a 42 kDa
outer membrane protein [13, 14]. These vaccines have
demonstrated impressive efficacy, however, manufacture
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requires isolation and detoxification of ApxI, ApxII and
ApxIII as well as the outer membrane protein, all from A.
pleuropneumoniae. Therefore, an alternative, lower cost,
production method that could improve vaccine efficacy is
desired.
A number of A. pleuropnuemoniae surface structures
have been reported to be involved in adhesion and col-
onisation including fimbriae [15], lipopolysaccharide
(LPS) [16] and autotransporter adhesins [17]. Recently, a
family of N-linked protein glycosylation pathways has
been described. In the prototype pathway, characterised
in Haemophilus influenzae, asparagine residues of the
outer membrane adhesin protein, HMW1A, are deco-
rated with hexose and dihexose residues by the cytoplas-
mic glycosyltransferase HMW1C [18, 19]. The genes
encoding this system are collocated on the chromosome.
Glycosylation of HMW1A by HMW1C has been shown
to confer protection against proteolytic degradation dur-
ing secretion and facilitates tethering of the adhesin to
the cell surface [18]. An analogous adhesin/glycosyl
transferase system has also been identified in A. pleurop-
neumoniae, the in vitro and in vivo properties of which
have been recently reported [20–23]. Unlike hmw1A/C,
the A. pleuropneumoniae N-glycosyl transferase gene,
ngt, is not located adjacent to an obvious acceptor pro-
tein adhesin gene. This is similar to the recently de-
scribed systems of Kingella kingae and Aggregatibacter
aphrophilus [24], whereby these ‘orphan’ HMWC family
of transferases are distally encoded from their targets.
Unique to A. pleuropneumoniae, the ngt operon also
encodes a polymerising α1,6-glucosyltransferase, agt,
which elongates N-linked glucose. To date, confirmed
substrates of this system are limited to autotransporter
adhesins [21]. NGT is an inverting glycosyl transferase
that exhibits similar acceptor site specificity to the
eukaryotic oligosaccharyltransferase consensus sequon,
NX(S/T), where X is any amino acid except proline [20].
Recombinant expression of ngt and agt with an appro-
priate acceptor protein results in the modification of tar-
get asparagine with a glucose homopolymer with a chain
of up to 29 repeat units [23]. This modification is detect-
able by immunoblot analysis with an antibody raised
against a tetrasaccharide of α1,6-linked glucose (dex-
tran). However, immunofluorescence studies failed to
detect this epitope in permeabilised A. pleuropneumo-
niae cell extracts. This suggests that although ngt and
agt have the capacity to form extended glucose polymer,
this is not observed in native-like conditions, indicating
that the native polymer may not exceed 4 units. Deletion
of ngt and agt was shown to reduce A. pleuropneumo-
niae adhesion to a human epithelial cell line [23], dem-
onstrating a potential importance in colonisation and
virulence. Furthermore, the glycosylation system is abso-
lutely conserved across A. pleuropnuemoniae isolates,
making it one of the most attractive targets for subunit
vaccine development [25].
Glycoconjugate vaccines provide superior immunity
compared with polysaccharides alone. The attachment
of a sugar molecule to a typical T cell antigen (such as
protein) induces memory T proliferation, memory B cell
development and formation of polysaccharide-specific
IgM to IgG switching. The H. influenzae HMW1/2 gly-
cosylated adhesins have been extensively studied as po-
tential vaccine candidates against otitis media infection
in children and chronic obstructive pulmonary disease
in adults due to their well-conserved nature (encoded
in 75% H. influenzae strains), abundance of epitopes
on the cell surface and ability to induce a protective
immune response [26–29]. As such, a vaccine that
combines the polyglucose glycan (highly conserved,
abundant on the cell surface) and the Apx toxins (in-
duces a protective immune response) has the potential
to confer enhanced protection against all A. pleurop-
neumoniae serotypes.
Recombinant expression of these components in E.
coli represents a convenient way to produce an inex-
haustible and purified supply of glycoconjugate-based
vaccines, thereby reducing production costs compared
with current methods. However, the use of biological
conjugation systems to functionally transfer key glycosyl
transferase genesto the chromosome of a convenient
host organism has the potential to reduce costs further
still. Stable integration of genes coding for transferase
enzymes has a number of advantages over current
methods for recombinant expression of vaccine candi-
dates. Firstly, it reduces the metabolic burden of main-
taining energetically costly and often unstable plasmids,
which can result in reduced cell viability and reduced
yield in batch fermentation [30]. Any move to reduce
this burden should, in theory, contribute to improving
the overall yield and reduce cost of production. A sec-
ond advantage of mastering this method is that it un-
locks the potential to generate live attenuated vaccine
strains expressing novel glycan antigens. Stable expres-
sion of a transferase system (with or without a corre-
sponding acceptor protein) in a clinically relevant
attenuated pathogen would confer protection against the
pathogen itself and against the resulting glycan intro-
duced from a second pathogen. The NGT system of A.
pleuropneumoniae lends itself well to this concept, as it
requires a relatively short acceptor sequon and the sys-
tem is comprised of only two transferases. Although
NGT does display some substrate preference to auto-
transporter adhesins, it can glucosylate other protein
classes that contain the correct acceptor sequon [21].
Introduction of NGT/AGT alone should result in the
formation of a cloned supply of host peptides modified
by A. plueropneumoniae glycan.
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We describe a method for the construction of candi-
date glycoconjugate vaccines against A. pleuropneumo-
niae. We use transposon-based integration system to
generate a recombinant E. coli cell with a single chromo-
somally encoded copy of ngt and agt, which we use to
modify soluble fragments of the immunogenic Apx
toxins. Our results suggest that modification of Apx
toxins by this system results in a glycoconjugate with a
native-like glucose modification.
Results
Chromosomal insertion of ngt and agt
One of the key considerations for the construction of
suitable E. coli strains for glycoengineering is the organ-
isation and fine-tuned expression of acceptor proteins,
glycosyl transferases and sugar biosynthesis loci onto
compatible expression plasmids. Finding plasmids with
appropriate compatibility groups can be a limiting factor
in the engineering process and antibiotic-based mainten-
ance of plasmids can impede cell growth. One way to
obviate the use of multiple plasmids is the integration of
one or more of these components onto the E. coli
chromosome. Furthermore, artificially increased expres-
sion of recombinant transferases can result in artefactual
products. For example, ngt and agt expression from a
high-copy plasmid (ColE1 ori, 15–20 copies) resulted in
hyper-glycosylation of the A. pleuropneumoniae auto-
transporter adhesin fragment, AtaC1866–2428. Figure 1,
(lanes 2 and 4) demonstrates the presence of a high mo-
lecular weight smear visible above the point at which
AtaC should migrate when resolved by SDS-PAGE.
NGT decorates AtaC1866–2428 with hexose at 15 Asn
sites with up to 29 units at each site [23]. However, im-
munoreactivity with anti-dextran monoclonal antibody
was not observed in A. pleuropneumoniae cell extracts
and only single hexose units on autotransporter adhesins
were detected by mass spectrometry analysis [21]. Thus,
we concluded that ectopic expression of ngt and agt
from high copy number plasmids results in an artificial,
hyper-polymerised glycan on its target acceptor protein.
To overcome these two constraints we used the pUT
mini-Tn5 transposon [31] to integrate ngt and agt, under
the transcriptional control of a lac promoter, into the
chromosome of E. coli BL21 cells. Our transposon-
delivered cargo also included the lacI repressor. This gener-
ated an E. coli strain with a single chromosomal copy of ngt
and agt, transcriptional controlled by lacI/T7 polymerase
for inducible protein expression. Glycosylation of AtaC
using this strain resulted in the absence of a smear on a gel,
suggesting that this hyperglycosylation was indeed a prod-
uct of multicopy plasmid-borne transferase expression.
ApxIA calcium-binding domain is a soluble suitable
candidate for glycoengineering
Recombinant expression of the Apx toxins has been re-
ported to result in the formation of insoluble inclusions
bodies [32–34]. The presence of extensive regions of
hydrophobicity at the N-terminus (including nine amphi-
pathic α-helices), responsible for the formation of cation-
selective pores in target cell membranes [35, 36], largely
explains this apparent insolubility. Although some glyco-
proteins are insoluble or membrane bound [37, 38], glyco-
sylation is a soluble phenomenon and we speculated that
the formation of inclusions bodies would hinder cytoplas-
mic glycosylation of our acceptors by NGT. Therefore,
three fragments of the ApxIA toxin, termed ‘hydrophobic
domain’, ‘activation domain’ and ‘calcium-binding domain’,
were constructed as outlined in Fig. 2a. While expression
of the hydrophobic domain in E. coli BL21 cells resulted
in detectable protein, this was mostly confined to the
Fig. 1 Demonstration of glycosylation of the peptide AtaC1866–2428 by a single chromosomal copy or multiple plasmid copies of the ngt and agt
operon. Glycosylated AtaC was resolved by SDS-PAGE and detected by coomassie staining (left panel) or immunoblot analysis (right panel),
probed with anti-6xHis (green) and anti-dextran (red) antibody
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insoluble fraction (Fig. 2b and c), consistent with reported
observations. The calcium-binding domain fragment
expressed well, was detectable in the soluble fraction
and purified by nickel-affinity chromatography (Fig. 2c,
lane 7). Expression of the activation domain was not
detectable under these conditions (Fig. 2c). In an at-
tempt to solubilise the hydrophobic domain, two
N-terminal maltose-binding protein (MBP)-fusions
were constructed. However, expression of this fusion
protein did not improve solubility of the hydrophobic
domain, which also expressed relatively poorly (Fig. 2c,
lanes 11 and 12). Consequently, the calcium-binding
domain of ApxIA emerged as the most promising can-
didate for construction of a glycoconjugate vaccine.
Engineering of NX(S/T) glycosylation sequons into
ApxIAD3
Although ApxIA encodes 3 NX(S/T) sequons that could
be targets for NGT, none of these are present within the
calcium-binding domain. Therefore, N- and C- terminal
NAT sequons were engineered into the amino acid se-
quence, along with a series of internal modifications to
generate appropriate acceptor sites (Fig. 3a). Toxin
fragments were expressed in BL21 with and without
chromosomally encoded ngt and agt, purified and re-
solved by SDS-PAGE. Unlike glycosylation of AtaC with
plasmid-borne ngt and agt, no high molecular weight
smearing was observed (Fig. 3b, also see Fig. 5). Toxin
fragments migrated at a comparable molecular weight
with and without the presence of the transferases. This
was consistent with the notion that a shorter glycan
had been transferred. Periodic acid-Schiff (PAS) stain-
ing was performed to determine whether decoration of
these peptides by NGT had been achieved (Fig. 3c).
Fragments with the internal modifications G71 T and
G114 T were positively stained magenta by the Schiff
reagent suggesting that they had been successfully
modified. No staining of the V83 T modified fragment
was observed, suggesting that glycosylation had not oc-
curred despite the presence of N- and C- terminal NAT
sequons. However, this fragment expressed poorly com-
pared with the other fragments, suggesting that that inclu-
sion of a consensus sequon is not the only predetermining
factor for glycosylation by NGTand that relative abundance
of the target peptide may also be influential.
Construction of an ApxIIA glycoconjugate
Although apxIA is a key virulence determinant for A.
pleuropneumoniae infections, it is not expressed by all
virulent serotypes [4]. Thus, we explored whether this
method could be utilised to construct glycoconjugate vac-
cines for other Apx toxins. ApxI demonstrates greater
toxicity than ApxII towards alveolar macrophages and
polymorphonuclear neutrophils [39]. However, apxII is
A
B C
Fig. 2 Expression and solubility of ApxIA peptide fragments. a- Schematic representation of the domain architecture of ApxIA. b- The ‘hydrophobic’
domain (D1) and Ca2+-binding domain (D3) of ApxIA were recombinantly expressed in E. coli, lysed and soluble and insoluble fractions were resolved
by SDS-PAGE. c- Expression and solubility of ApxIA fragments immunoblot detected using an anti-6xHis (green) antibody. Lane 1: Ladder; lane 2: E. coli
expressing ApxIAD3 (soluble); lane 3: ApxIAD1; lane 4: ApxIAD2; lane 5: MBP-ApxIAD1 fusion; lane 6: MBPNlinker-ApxIAD1 fusion; lane 7:
ApxIAD3 Ni-NTA affinity purified; lane 8 ApxIAD3 (whole cell lysate); lane 9: ApxIAD1; lane 10: ApxIAD2; lane 11: MBP-ApxIAD1 fusion; lane
12: MBPNlinker-ApxIAD1 fusion
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expressed by all serotypes except 10 and 14 and displays
moderate haemolytic and cytotoxic activity. ApxIV is only
expressed in vivo and is antigenically distinct from the
other Apx toxins [40]. Furthermore, ApxIVA displays a
distinct domain architecture from the other toxins,
which is reflected in their difference in molecular
weight (ApxIV = 202 kDa, ApxI/II = 105 kDa). Due to
the observed solubility and glycosylation of the ApxIA
Ca2+-binding domain, we limited our construction of
toxin fragments to the Ca2+-regions of ApxIIA and
ApxIVA.
Unlike ApxIA, the calcium-binding domains of ApxIIA
and ApxIVA naturally contain potential sites for NGT gly-
cosylation (1 and 6 sites respectively). For vaccine-fragment
construction purposes, the calcium-binding region of
ApxIVA was divided into two discrete 35 kDa peptides.
ApxIIA was further modified (G64T) to include an add-
itional internal NDT sequon (Fig. 4a). N- and C-terminal
NAT sequons were introduced into all fragments and pep-
tides were expressed in E. coli with and without a single
chromosomal copy of ngt and agt. No shift in electro-
phoretic mobility was observed (Fig. 4b) in the two
ApxIVA domains and both were negative by PAS stain-
ing (data not shown). A partial shift in electrophoretic
mobility was observed for the ApxIIA fragment (Fig. 4b),
which also stained positively with Schiff reagent (Fig. 4c)
demonstrating that glucosylation had occurred. In agree-
ment with ApxIA glyconconjugate fragment construction
(Fig. 3), the presence of recognition sequons within a
peptide sequence is not necessarily indicative of glycan
modification.
Glycosylation of Apx toxin fragments by chromosomally
encoded ngt and agt result in a shorter, native-like glycan
To assess the polymerisation state of the glucose modifi-
cation, Apx fragments were probed by immunoblotting
with an anti-dextran monoclonal antibody. No reactivity
with any of the toxin fragments was observed suggesting
that these are not decorated with a glucose polymer
(Fig. 5). This observation, taken with the positive PAS
stain for fragments ApxIAD3 (G71 T), ApxIAD3 (G114)
and ApxIIAD3 (G64 T) (Fig. 3c), suggests that these pep-
tides are modified by NGT and AGT but with no more
than 4 glucose units at each site. Given that immunofluor-
escence studies failed to detect a glucose polymer epitope
in A. pleuropneumoniae cell lysates [23], we propose that
a short glucose repeat unit is representative of a more
native-like glycan modification.
A
B C
Fig. 3 Glycosylation of ApxIAD3 (Ca2+-binding domain). a- Schematic representation of ApxIAD3. The peptide sequence was engineered to
include N- and C-terminal NAT sequons as well as three separate internal modifications. The three ApxIAD3 variants were expressed in E. coli with
and without chromosomally encoded ngt and agt. The fragments were purified by Ni-NTA affinity chromatography, resolved by SDS-PAGE and
detected by either coomassie stain (b) or the presence of glycoprotein detected by PAS staining (c)
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Apx toxin fragments are glycosylated with 1–4 hexose units
In order to determine the number of glucose units at-
tached to toxin fragments we performed intact MALDI-
MS analysis on ApxIA (G71 T) and ApxIIA (G64 T) puri-
fied from cells with and without ngt and agt encoded on
the chromosome. Comparison of the most intense peaks
of the glycosylated and unglycosylated forms of ApxIA
demonstrates a shift in mass by 162 Da, indicative of a
hexose modification (Fig. 6a). Subsequent less intense
peaks suggest as many as three hexose units decorate the
glycosylated form of ApxIA. Given that ApxIA (G71 T)
has three NX(S/T) sequons (hence, three available sites
for glycosylation by NGT), it was not immediately clear
whether this data suggests occupation of all sites by a sin-
gle hexose, or by one or two sites with more than one hex-
oses. Similarly, comparison of the most intense peaks of
glycosylated and unglycosylated forms of ApxIIA also in-
dicates a mass shift of 162 Da (Fig. 6b). The ApxIIA frag-
ment contains four potential glycosylation sites and the
MALDI spectrum suggests a modification of up to four
hexose units. Taken together, these observations indicate
that the dominant glycoform of the peptide was modi-
fied with a single hexose at a single site. In order to
confirm the identity of the observed modification, we
performed LC-MS/MS analysis of the glycosylated
A
B C
Fig. 4 Glycosylation of ApxIVAC1, ApxIVAC2 and ApxIIAD3 (Ca2+-binding domain). a- Schematic representation of ApxIVAC1, ApxIVAC2 and
ApxIAD3. Each peptide was engineered to include N- and C-terminal NAT sequons. ApxIAD3 was further modified to include an internal NDT
motif. b- The toxin fragments were expressed in E. coli with and without chromosomally encoded ngt and agt. The fragments were purified by
Ni-NTA affinity chromatography, resolved by SDS-PAGE and detected by coomassie staining. c- The following Ni-NTA purified fragments were
resolved by SDS-PAGE and PAS stained: Lane 1: ApxIA (no NX(S/T) sequons); Lane 2: ApxIA (G71 T), no ngt and agt Lane 3: ApxIA (G71 T) plus
chromosomally encoded ngt and agt; Lane 4: ApxIIA, no ngt and agt; Lane 5: ApxIIA plus chromosomally encoded ngt and agt; Lane 6: AtaC,
plasmid-encoded ngt and agt
Fig. 5 Apx toxin fragments expressed in E. coli with and without
chromosomally encoded ngt and agt, were resolved by SDS-PAGE
and detected by immunoblot analysis probed with anti-6xHis
(green) and anti-dextran (red) antibody. Lanes 2/3: ApxIAD3 (G71
T); lanes 4/5: ApxIAD3 (V83 T); lanes 6/7: ApxIAD3 (G114 T); lanes 8/
9: ApxIIAD3 (G64 T); lanes 10/11: ApxIAD1 (whole cell lysate); lane
12: E. coli expressing AtaC1866–2428 and plasmid encoded ngt
and agt
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peptides (Table 1, Additional file 1: Table S1 (full LC-MS/
MS output) and annotated spectra in Additional file 2:
Figure S1, Additional file 3: Figure S2, Additional file 4:
Figure S3). The N-terminal peptide GSNATDISVGK
(ApxIA) was identified as being modified with up to 4
hexose units. The peptide GDDEIYGNDTHDILYGDD
GNDVIHGGDGNDHLVGGNGNDR (ApxIA) was deco-
rated with 2 hexose units, although the modified aspara-
gine could not conclusively be assigned (Table S1).
However, the NDT sequon represents the most plausible
location of the hexose addition. No hexose modification
was detected on the C-terminal NAT sequon. By contrast,
the ApxIIA C-terminal sequon was modified with 1–3
hexoses. Similar to the ApxIA fragment, the N-terminal
peptide (GSNATVGNREEK) was modified with 1–4 hex-
oses. The internal peptide, GDGNDSITDSGGQDK, was
modified with 1–2 hexoses. Overall, these data demon-
strate that AGT was active when expressed as a single
copy encoded on the chromosome. The absence of an ex-
tended glucose homopolymer is consistent with previous
observations that both glycosylated and unglycosylated
peptides resolve at a comparable molecular weight and do
not react with an anti-dextran antibody. We propose a
shorter glucose polymer may represent a more native-like
glycan and thus represents more appropriate modification
for a subunit vaccine.
Discussion
In this study, we report the design and construction of
A. pleuropneumoniae glycoconjugate vaccine candidates.
These candidates, based on peptides derived from the
ApxIA and ApxIIA toxins coupled with a conserved
Fig. 6 In-tact MALDI-MS analysis of purified ApxIA (a and c) and ApxIIA (b and d) expressed from wild type E. coli (upper panels) and with ngt
and agt encoded on the chromosome (lower panels). a and b are peaks corresponding to singly charged ions, c and d are peaks corresponding
to doubly charged ions. The mass shift in the peaks observed in the lower panel in each figure correspond to the addition of hexose units
Table 1 Identification of glycosylated peptides
Peptide Tryptic peptide sequence Glycan modification Glycan location
ApxIA GSNATDISVGK Hex1–4 1xHex (4) [N3(100)]
ApxIA GDDEIYGNDTHDILYGDDGNDVIHGGDGNDHLVGGNGNDR Hex2 2xHex [N]
ApxIIA GSNATVGNREEK Hex1–4 1xHex (4) [N3(100)]
ApxIIA LAFNATK Hex1–3 1xHex (3) [N4(100)]
ApxIIA TGDGNDSITDSGGQDKLAFNATK Hex 1–2, Hex2 1xHex (2) [N5(100)]; 2xHex [N5(100); N20(100)]
ApxIIA TGDGNDSITDSGGQDK Hex1 1xHex [N5(100)]
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glycan, have the potential to confer protection against all
known virulent serovars of A. plueropnuemoniae. Fur-
thermore, we present a convenient mechanism for con-
struction of recombinant glycoproteins by integrating
the glycosyltransferases onto the host chromosome. We
propose that this results in a more native-like glycan and
has the added benefit of reducing metabolic burden of
maintaining an additional expression plasmid.
Currently, vaccines against A. pleuropneumoniae are
based on either inactivated whole cell-bacterins or the
Apx toxins. While bacterins offer good protection
against the vaccination strain, they offer limited
cross-protection against other serotypes [41, 42]. Vaccin-
ation with Apx toxins results in reduced morbidity asso-
ciated with infection but no vaccine to date has been
effective in preventing colonisation [42, 43]. Conse-
quently, asymptomatic carriage can increase the risk of
infection in non-vaccinated pigs within the herd. Both
bacterins and current toxin-based vaccines rely on
large-scale growth of live A. pleuropneumoniae for pro-
duction. The use of recombinant E. coli offers a safer
and more tractable means to generate A. pleuropnuemo-
niae vaccine candidates. Identifying protective antigens
that offer cross-serotype protection, reduce disease
symptoms and prevent colonisation remains a challenge.
However, E. coli confers greater flexibility to overcome
some of the problems associated with current methods.
Recently, the fimbral protein, ApfA, and outer mem-
brane lipoprotein, VacJ, were identified as promising vac-
cine candidates, due to the fact that they are surface
exposed and well-conserved across serotypes [44]. Vac-
cination with these proteins resulted in increased IgG
titre when outer membrane vesicles were used as an ad-
juvant. However, despite a promising antibody response,
this did not translate into effective protection against A.
pleuropneumoniae infection [45]. Therefore, the toxins
remain the most relevant candidates for prevention of
disease. We propose that construction of a glycoconju-
gate that combines a glycan involved in initial cell at-
tachment with toxin fragments may offer protection
against colonisation and disease progression.
In this study, we demonstrate a method for construc-
tion of a short polymer glycoconjugate, which is more
representative of the native glycan epitope. Using E. coli
as tool for bioengineering of glycoconjugate vaccines has
a number of advantages, as well as some challenges,
compared with using the original host organism. Previ-
ous work has demonstrated that expression of ngt and
agt from a multi-copy plasmid results in a glycan modi-
fication not detectable in A. pleuropneumoniae itself
[20, 22, 23]. Balancing the requirement for high yield of
recombinant vaccine without generating non-native
by-products was overcome by integrating single copies
of the transferases onto the chromosome. Previous
observations demonstrate that HMWC1-like transfer-
ases demonstrate greater specificity towards their cog-
nate autotransporter adhesins and non-cognate E. coli
outer membrane proteins [21]. However, they also dem-
onstrate specificity towards sequon-containing peptides
that are highly abundant (e.g. DnaK) [21, 46]. We found
that chromosomally encoded ngt and agt and expres-
sion of the toxin fragment substrate from a high copy
vector resulted in a high yield of soluble vaccine with a
shorter glycan (1–4 hexoses) modification.
Recombinant multicomponent subunit toxin-based
vaccines have been demonstrated to provide cross pro-
tection against a number of A. pleuropnuemoniae sero-
types [34]. The use of E. coli to produce immunogenic
peptides obviates the requirement to use virulent strains
of A. pleuropneumoniae in the vaccine production
process. However, a number of studies have highlighted
the issue of poor solubility when recombinantly express-
ing Apx toxins [32–34]. A recent study demonstrated
that an ApxI/II/III triple fusion peptide, expressed in E.
coli, could offer protection in a murine challenge model
when delivered in outer membrane vesicles [47]. The
peptide portion of each toxin incorporated into the fu-
sion vaccine was remarkably similar to that described
in this study i.e. the calcium-binding domain. Crucially,
this research demonstrated that the Apx hydrophobic
pore-forming domain does not necessarily need to be
included in the vaccine composition for it to provide
protection and that other toxins domains can constitute
immunogenic epitopes. Here, the calcium-binding do-
mains were fused to cytolysin A (ClyA) in order to elicit
high antibody titres. Whether the calcium-binding do-
mains alone are sufficient to stimulate a protective im-
mune response warrants further investigation. However,
glycosylation of such a fusion by NGT and AGT should be
feasible, given that ClyA can be expressed as a soluble
peptide. Using soluble fragments is an absolute require-
ment for glycosylation by cytoplasmic glycosyl transfer-
ases but also alleviates challenges associated with
purification of peptides from inclusion bodies. Another
strategy for generating soluble toxin epitopes is to fuse
them to other immunogenic peptides. One study dem-
onstrated that immunisation of mice with the fragment
DDEIYGNDGHP fused to E. coli heat labile entero-
toxin, EtxB, elicited formation of haemolysin neutralis-
ing antibodies in mice [9]. This peptide is also part of
the calcium-binding domain fragments constructed in
this study, although we modified the peptide sequence
to DDEIYGNDTHP (ApxIA G71 T) in order to form an
NGT acceptor sequon. Taken together, these observa-
tions suggest that regions of the toxins other than the
pore-forming domains can be used to elicit an immune
response, but they are often coupled to other immuno-
genic peptides.
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While a native-like glycan may be more desirable for
an A. pleuropneumoniae vaccine, dextran-based conju-
gates have been shown to be useful vaccines against
bacteria such as Helicobacter pylori [48]. Here, three
dextrans with average molecular masses of 5 kDa, 3.5
kDa and 1.5 kDa were fused to tetanus or diphtheria tox-
oid. These glyconconjugates were immunogenic in rab-
bits and mice and post-immune sera demonstrated
reactivity with α(1–6)-glucan positive strains of H. pylori
[48]. We present evidence that the length of the glycan
can be tailored to generate either a long or a short chain
by varying the copy number of the transferases. Further-
more, the H. influenzae adhesins have been proposed as
potential vaccine candidates due to their conserved na-
ture and contribution to colonisation [26–29]. Although
the effect of the glucose modification on adhesin folding
and trafficking is well studied [18, 19, 49–51], its inter-
action with the immune system is currently poorly
understood. While these studies have demonstrated the
protective properties of antibodies raised against these
adhesins, they did not explore whether the glycan itself
represents a true epitope. Combining the glycan with a
toxin fragment represents a novel approach to generat-
ing antigens that may be important in colonisation.
Glycosylation of acceptor sequons was only observed
in 3 out of 6 toxin fragment peptides tested, despite all
peptides containing terminal NAT sequons. We used
LC-MS/MS to demonstrate glycosylation of the follow-
ing sequons: SNATD (N-terminal, ApxIA), SNATV
(N-terminal, ApxIIA) GNDSI (internal, ApxIIA) and
FNATK (C-terminal, ApxIIA). Three out of four pep-
tides contained non-polar residues at the − 1 position
(the other being Ser). One out of four contained Asp at
the + 1 position (the other being Gly). The presence of a
Asp residue at the + 1 position was shown to be inhibi-
tory to glycosylation by a recent study [52]. However,
our evidence suggests that an Asp at the + 1 position
was not an obstacle to glycosylation by NGT, which is
consistent the observation that numerous NDT sites
within autotransporter adhesins were modified by
ApNGT, when expressed in E. coli [21, 23]. Asp (nega-
tive), Arg (positive), Ile and Val (both non-polar) occupy
the + 3 position. By contrast, the sites that were not glu-
cosylated include GNDTI (ApxIA V83 T), NNLSG,
GNDTL, GNDTI, INGSY (all ApxIVAC1), GNDTV and
INLSE (both ApxIVAC2). Similar to those peptides that
were glycosylated, 7 of 8 contain non-polar residues at
the − 1 position (the other being Asp). A combination of
non-polar and negatively charged residues were ob-
served at the + 1 position (3 non-polar, 4 Asp). Taken to-
gether, we can infer no reason in principle why the
primary amino acid sequence of these unglycosylated
peptides alone should be intrinsically prohibitive to
modification by NGT. Therefore, we propose that the
absence of glycosylation may be a consequence of poor
substrate protein expression. Our data indicated that
the vaccine candidates that demonstrated the greatest
stability or abundance were the substrates that were
glycosylated.
LC-MS/MS analysis demonstrated that toxin frag-
ments were decorated with between 1 and 4 hexoses.
The N-terminal NAT sequons were modified with 4
hexoses in both ApxIA and ApxIIA fragments. By con-
trast, the C-terminal NAT sequon and internal NDS
sequon of ApxIIA were decorated with 1–2 or 1–3 hex-
oses, respectively. The reasons for this heterogeneity
are unclear, but suggest that AGT may demonstrate
some substrate site specificity. Whether this is dictated
by primary amino acid structure warrants further inves-
tigation. However, immunisation with heterogeneous
glycoforms presents the immune system with a variety
of different epitopes, which could be advantageous. In
fact, almost all chemically conjugated glyconconjuate
vaccines are heterogeneous in regards to polysaccharide
length and attachment site [53, 54].
Conclusions
We describe a method for the assembly of novel glyco-
conjugate vaccine candidates to protect pigs against the
respiratory pathogen, A. pleuropneumoniae. By integrat-
ing NGT and AGT into the E. coli chromosome we were
able to generate Apx toxin fragments modified with a
glycan that more closely resembles that observed on A.
pleuropnuemoniae high molecular weight adhesins.
While toxins confer the best protection against disease,
reducing colonisation limits the risk of disease spread by
asymptomatic carriers. Conjugating a toxin fragment
with an adhesin-associated glycan offers a novel ap-
proach to generating epitopes that may be important for
both colonisation and disease.
Materials and methods
Bacterial strains and culture conditions
Bacterial strains and plasmids used in this study are listed
in Additional file 5: Tables S2 and Additional file 6: Table
S3 respectively. E. coli strains were cultured in LB broth
or agar (Merck, Millipore) at 37 °C and supplemented,
when required, with 50 μgml− 1 kanamycin, 100 μgml− 1
ampicillin, μg ml− 1 100 μgml− 1 zeocin, 100 μgml− 1 tri-
methoprim and diaminopimelic acid (DAP).
Chromosomal integration of ngt/agt
A chromosomal insertion of ngt and agt was generated
using the mini-Tn5 Km transposon system. Briefly, ngt,
agt and the lacI repression were amplified from the plas-
mid pEXT20ngtagt by PCR (Phusion polymerase, New
England Biolabs [NEB]) (see Additional file 7: Table S4
for primers used), restriction enzyme digested with NotI
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(NEB) was and ligated into pUC57, generating plasmid
pUC57ngtagt. pUC57ngtagt was digested with SfiI and
ligated into plasmid pUTminiTn5Km2, generating
pUTTn5ngtagt, which was transformed into Mu Free
Donor (MFD) conjugative strain, a DAP auxotroph [55].
Overnight cultures of MFD and BL21 were subcultured
into LB and grown to exponential phase. Cells were
sedimented by centrifugation and pellets resuspended in
phosphate buffered saline (PBS, Sigma). Cell suspensions
were mixed in a 3:1 donor:recipient ratio and were spot-
ted onto antibiotic-free LB agar plates supplemented
with DAP, which were grown for 16 h at 37 °C. Cells
were scraped from the agar surface using a loop and re-
suspended in PBS, serial diluted and plated on zeocin se-
lective LB agar plates, without DAP. Colonies were
replica plated onto zeocin and ampicillin plates to select
for integration into the chromosome and loss of the
plasmid backbone (Zeocin resistant, ampicillin sensitive).
Cloning and synthesis Apx toxin fragments
ApxIA fragments corresponding to the ‘hydrophobic’
domain (D1), ‘activation’ domain (D2) and calcium bind-
ing domain (D3) were amplified by PCR from a genomic
DNA extraction of A. pleuropneumoniae L20 (serotype
5b) [56] using the primers shown in Table S4. PCR prod-
ucts were digested with BamHI and HindIII and ligated
into digested pUC19 and pET28a. Plasmids sequences
were verified by Sanger sequencing and transformed into
E. coli BL21. All toxin fragments contained N-terminal
hexa His tags for Ni-NTA affinity purification.
MBP constructs were generated using a malE gene
fragment synthesised by Integrated DNA Technologies
(IDT), USA, (see Additional file 8: Figure S4 for se-
quence). Primer pairs apxIAD1MBP_F/apxIAD1MBP_R
and apxIAD1MBP_F/apxIAD1MBPNlinker R were used to
amplify MBP alone and MBP with an asparagine-linker
region. PCR products were digested with BamHI and
EcoRI and ligated into pET28a. ApxIAD1 was amplified
from pUC19apxIAD1 using primers MBPapxIAD1_F2
and apxIAD1_R. The PCR product was digested with
SacI and HindIII and ligated into pET28a containing
MBP or MBPNlinker.
ApxIAD3 fragments with N- and C-terminal NAT
sequons and internal NAT sequon were synthesised as
gBlocks by IDT (see Additional file 8: Figure S4 for se-
quence). Constructs were restriction enzyme digested
with PstI and EcoRI and subcloned pUC19. These plas-
mids served as the template for amplification with
apxIAD3NAT primers. PCR products were restriction
enzyme digested with BamHI and HindIII ligated into
pET28a.
ApxIIAD3, ApxIVAC1 and ApxIVAC2 fragments
were synthesised as gBlocks by IDT, codon optimised
by expression in E. coli (see Additional file 8: Figure S4
for sequences). Constructs were restriction enzyme
digested with BamHI and HindIII ligated into pET28a.
Expression and purification of Apx toxin fragments
Plasmids encoding Apx toxin fragments were trans-
formed into BL21 and BL21::ngtagt. Strains were cul-
tured in LB broth, in an orbital shaker, supplemented
with appropriate antibiotics to early exponential phase
(OD600nm= 0.5) upon which expression was induced by
the addition of 1mM Isopropyl β-D-1-thiogalactopyrano-
side (IPTG, Sigma). Cultures were incubated for a further
16 h, sedimented by centrifugation and resuspended in 50
mM Tris HCl pH 8, 300mM NaCl, 10mM imidazole. Cells
were lysed using BeadBug zirconium lysing tubes (Sigma)
in a FastPrep homogeniser (MP Biomedicals) and insoluble
material was removed by pelleting. Toxin fragments were
subsequently purified from cell lysates by Ni-NTA affinity
chromatography and eluted in 50mM Tris HCl pH 8, 300
mM NaCl, 300mM imidazole.
Immunoblot analysis
Peptides were resolved by SDS-PAGE and transferred
to nitrocellulose membranes using the iBlot 2 dry blot-
ting system (ThermoFisher). Membranes were blocked
for 1 h in PBS containing 2% (w/v) skimmed milk pow-
der. Primary antibodies, Rabbit anti-6xHis antibody
(Abcam, UK, used at a dilution of 1:10000) and mouse
anti-dextran (MS α-Dextran Clone Dx1, Stem Cell
Technologies, Canada, used at a dilution of 1:2000) sus-
pended in PBS containing 2% w/v skimmed milk pow-
der and 0.1% (v/v) Tween 20, were incubated with the
membrane for 1 h. Membranes were washed three
times with PBS and incubated for 45 min with a sec-
ondary goat anti-rabbit IgG IRDye680 or goat anti-
mouse IgG IRDye800 (LI-COR Biosciences, UK, both at
a dilution of 1:10000). Fluorescent signal was detected
with the Odyssey LI-COR detection system (LI-COR
Biosciences, UK).
Periodic acid Schiff (PAS) staining
Apx toxin fragments were purified by Ni-NTA affinity
chromatography, protein concentration was quantified
using Bradford reagent (Sigma) and equal amounts of
protein were resolved by SDS-PAGE. Gels were fixed in
50% (v/v) methanol and PAS staining was performed
using the Pierce Glycoprotein Staining Kit (ThermoFisher)
according to the manufacturer’s instructions.
LC-MS/MS
Protein solutions were subjected to reduction (DTT)
and alkylation (iodoacetamide) prior to overnight diges-
tion with trypsin (Promega, Winsconsin, USA). After di-
gestion, the solutions were pipetted into sample vials
and placed in the LC autosampler.
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LC-MS/MS experiments were performed using a Dionex
Ultimate 3000 RSLC nanoUPLC (Thermo Fisher Scientific
Inc., Waltham, MA, USA) system and an Orbitrap Lumos
mass spectrometer (Thermo Fisher Scientific Inc., Wal-
tham, MA, USA). Peptides were loaded onto a pre-column
(Thermo Scientific PepMap 100 C18, 5 μm particle size,
100A pore size, 300 μm i.d. × 5mm length) from the Ul-
timate 3000 auto-sampler with 0.1% formic acid for 3min
at a flow rate of 10 μL/min. After this period, the column
valve was switched to allow elution of peptides from the
pre-column onto the analytical column. Separation of pep-
tides were separated by C18 reverse-phase chromatography
at a flow rate of 300 nL/min and a Thermo Scientific
reverse-phase nano Easy-spray column (Thermo Scientific
PepMap C18, 2 μm particle size, 100A pore size, 75 μm
i.d. × 50 cm length) at a flow rate of 300 nL/min). Pep-
tides were loaded onto a pre-column (Thermo Scien-
tific PepMap 100 C18, 5 μm particle size, 100A pore
size, 300 μm i.d. × 5 mm length) from the Ultimate
3000 autosampler with 0.1% formic acid for 3 min at a
flow rate of 10 μL/min. After this period, the column
valve was switched to allow elution of peptides from
the pre-column onto the analytical column. Solvent A
was water + 0.1% formic acid and solvent B was 80%
acetonitrile, 20% water + 0.1% formic acid. The linear
gradient employed was 2–40% B in 30 min. (Total LC
run time was 60 mins including high organic wash step
and column re-equilibration).
The eluted peptides from C18 column LC eluant were
sprayed into the mass spectrometer by means of an
Easy-Spray source (Thermo Fisher Scientific Inc.). All
m/z values of eluting peptide ions were measured in an
Orbitrap mass analyzer, set at a resolution of 120,000
and were scanned between m/z 380–1500 Da. Data
dependent MS/MS scans (3 s cycle time) were employed
to automatically isolate and fragment precursor ions and
generate fragment ions by higher energy collisional-
induced dissociation (HCD) (Normalised Collision Energy
(NCE): 38%) in the ion routing multipole. The resolution
of the Orbitrap was set to 15,000 for the measurement of
fragment ions. Singly charged ions, ions with greater than
seven charges and ions with unassigned charge states were
excluded from being selected for MS/MS and a dynamic
exclusion window of 70 s was employed.
Post-run, the data was processed using Protein Discov-
erer (version 2.1., Thermo Scientific). Briefly, Orbitrap raw
files were searched using SequestHT algorithm against
database containing the ApxIA or ApxIIA proteins and
common contaminant proteins (such as trypsin, BSA and
keratins). Static modification carbamidomethyl on cyst-
eine was applied. Also were considered the dynamic
modifications of 1, 2, 3, and 4 hexose units on aspara-
gine (+ 162.1 Da, + 324.1 Da, + 486.2 Da and + 648.2 Da
respectively). The peptide and fragment mass tolerances
were set to 20 ppm and 0.5 Da, respectively. FDR was esti-
mated with Percolator node and glycosylation site reliabil-
ity was calculated with ptmRS node. Only high-confidence
peptides (FDR < 1%) and glycosylation sites (ptmRS sore
> 75%) were accepted in the consensus step. All identifica-
tions from common contaminant database were manually
removed.
Intact MALDI-MS
Samples were desalted with C18 Ziptip™ (Millipore) using
manufacturers protocol. Each eluent was left to dry on the
polished steel MALDI plate and 2 μl of 2,5- Dihydroxyace-
tophenone matrix (Sigma Aldrich) at 18mg/ml in ethanol
was applied on top. Spectra were acquired using Bruker
UltrafleXtreme MALDI mass spectrometer using positive
linear mode at up to 50% laser power. Bruker flexControl
3.4 software was utilized for MALDI MS spectra analysis.
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